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This edition of Multiple Sclerosis Journal includes reports from three randomised 
controlled trials (RCTs) of cognitive behaviour therapy1, aerobic training2 and energy 
conservation3 management for the treatment of MS fatigue.  The three trials were led by 
separate research teams as part of the Dutch TREFAMS-ACE consortium4. Each trial 
compared one of the active treatments against a standardised control condition of three 
45-minute individual face-to-face consultations with experienced and trained MS-nurses 
over a 4-month period.  The MS nurses gave patients a standardised brochure about 
fatigue. Patients had the opportunity to discuss their fatigue and set goals for managing 
fatigue.  In contrast, the three active treatments (summarised in the Table) included 12 
45 minute individual face-to face treatment sessions with a health professional over the 
same time period.  Participants in all three trials were followed up over 12-months. The 
primary outcomes, Checklist Individual Strengths (CIS20r)5 domain fatigue and Impact 
on Participation and Autonomy Questionnaire (IPA) 6 were identical in all studies. 
Secondary outcomes included the Modified Fatigue Impact Scale7 and the Fatigue 
Severity Scale8.   ECM showed no significant improvements over the control condition on 
any outcomes. The CBT and aerobic training RCTS reported positive effects on the 
primary and secondary fatigue measures at the end of treatment, but effects were lost at 
52-weeks follow-up.  None of the trials found a positive effect for the active interventions 
on IPA at any follow-up point.   
 
INSERT TABLE 1 ABOUT HERE 
 
The three trials have addressed several limitations prevalent in many RCTs of 
interventions for MS fatigue conducted to date, particularly exercise interventions 9.  
Multiple therapists have been included in each active arm making the results more 
generalizable. Attention has been paid to assessing treatment fidelity, measuring 
treatment compliance, and collecting serious adverse events. This makes it easy to 
determine that the active treatment interventions studied here are acceptable to patients 
and safe to administer, as reported adherence rates were high and adverse events low 
(none directly linked to the interventions themselves).  Further confirmation of 
acceptability can be inferred from the reports of drop-out during the intervention. This 
varied across the interventions with 7 out of 43 (16%) for exercise, 2 out of 44 for CBT 
(5%) and 8 out of 42 for EC (19%), suggesting the CBT treatment protocol may be the 
most acceptable intervention. .  
 
 
 Risk of bias has been minimised through concealed random allocation to treatment arms, 
assessors were blind to treatment arm allocation, and most patients were followed up 
even where they had dropped out of treatment. Furthermore, the studies provide good 
examples of clear and transparent reporting. The studies were registered with ISRCTN 
and the protocol published4. The trials are written following CONSORT guidelines10 and 
detailed descriptive data across all time points are presented in the appendices. The 
treatments in each arm are clearly described using TiDier guidance for describing 
complex interventions11.  
 
Despite these strengths, these trials do have some limitations.  One is the trials are open 
to attrition bias12.  The percentage of data lost to follow-up and final analysis is 
summarised in the Table.  The CBT and exercise RCTs lost substantially more participants 
from the control group than the experimental group at long term follow up. The ECM 
study excluded some participants from the final ITT analysis.  These weaknesses could 
have been partly addressed by including a treatment effect sensitivity analysis for 
attrition.  In addition, to provide a clearer picture of the subsample not included in the 
analysis, it would have been useful to see baseline characteristics of the participants for 
whom data have been analysed versus those lost to follow-up 12.   
 
We are also unconvinced by the need to design three RCTS rather one. The TREFAMS 
group argued that three RCTs each recruiting from two separate centres would minimise 
contamination across treatment arms4. Whilst this may be logistically simpler, 
randomising 137 of 266 patients overall to control arms with only between 42 and 44 
people per trial randomised to active interventions is an inefficient design.  With one 
large trial, a greater proportion of patients could have been randomised to active 
treatments providing greater power to detect treatment effects across interventions. 
Furthermore, while recruiting 266 patients to three studies is no small task, we have 
concerns about the power of the studies to detect important differences. 
 
The power calculations for the three studies accounted for 10% attrition rather than 20% 
attrition as stated in the papers.  Based on 20% attrition, sample sizes should have been 
50 per-group rather than 45.  A bigger issue is that the studies were not powered to detect 
appropriate effect sizes. The studies were powered to detect an 8-point difference on the 
CIS20R (SMD=0.63), which whilst being ‘clinically significant’, will likely be considerably 
larger than the minimum clinically important difference (MCID). We could find no 
published MCID for the CIS20R. However, for other fatigue measures, MCIDs are typically 
in the order of SMDs between .3 and .4 .13 The studies were also not explicitly powered to 
detect effects on the co-primary IPA outcome or any of the secondary outcomes. IPA is a 
general measure of quality of engagement in societal roles which can be influenced by a 
wide range of general and MS related factors other than fatigue, and as such one would 
expect smaller effects.  Underpowered studies lead to a higher risk of false negative 
results and as such limit inferences that can be drawn from the studies. Non-significant 
effects simply indicate that there is insufficient evidence to reject the null hypothesis, not 
that we can infer no treatment effect exists. 
 
 
Perhaps most importantly, without one large RCT, we cannot draw direct inferences 
about the three treatments approaches.  This is disappointing as to date, no trials have 
attempted to explore the relative efficacy of these three approaches.  To have a better 
understanding of how the findings across these three trials compare, we have converted 
the treatment effects reported for the CIS20R fatigue measure to standardised mean 
differences (SMD) and plotted these out against time below (see figure). Negative values 
favour the intervention. All three interventions show some effect in favour of the 
intervention at 16-weeks (but this is non-significant for the ECM group).  None are 
significant by 26 weeks, although the effect size for CBT is still moderate. None of the 
interventions show any effect after one year. 
 
INSERT FIGURE ABOUT HERE 
 
 We have also used these SMDs to conduct a multivariate meta-analysis using a fixed 
effect model, which allows for the estimation of the uncertainty around the differences in 
effect sizes across the three studies 14.  Bearing in mind this is indirect evidence, we have 
made some cautious inferences with respect to the different effects across studies.  The 
effect size for CBT compared to ECM is SMD=0.57 (95% CI: -.05 to 1.19) in favour of CBT 
and compared to exercise is SMD=0.22 (95% CI: -.38 to .82) in favour of CBT.  For exercise 
compared to ECM, SMD=0.35 (95% CI: -.27 to .97). The confidence intervals provide 
further evidence that compared to CBT and aerobic exercise, ECM is unlikely to be 
efficacious. However, there is less certainty to draw firm conclusions about CBT 
compared to aerobic exercise.  Obviously, there are just three studies here and a proper 
network meta-analysis is needed, including all published studies.  
 
Although we cannot use this indirect evidence to draw firm conclusions about the 
interventions studied, it helps to inform the design of future RCTs in this area.  ECM 
appears to have a small effect size at best (further limited by dropout) so is not worth 
further research on its own, particularly as there are now several EC studies showing 
small or null effects 15.   Future trials could use ECM as a better and more matched control 
condition for either exercise or CBT.  We also need to focus on how to maintain treatment 
effects in an illness where increasing disability, fluctuating symptoms and relapse are 
likely.   This may mean longer term treatments or booster treatment sessions.  Perhaps 
combining CBT and exercise would provide greater benefits.  We also need more 
mechanistic studies of fatigue in MS to design more optimal approaches.   
 
Future studies also need to be considerably larger than the three reported here. Power 
calculations need to account for larger attrition and number of primary outcomes.  The 
TREFAMS-ACE protocol suggests there may be secondary papers from these three trials 
exploring possible mechanisms of the treatment effects.   Whilst these future papers may 
be informative in terms of next steps, these trials are not well powered for mediation and 
moderation analyses.  Large trials with clearly embedded process analyses will help us to 
refine and personalise treatments 16.   
 Future RCTS in this area also need to be more pragmatic and consider broader 
generalisability.  These three trials were largely efficacy trials.  Patients with high 
Hospital Anxiety and Depression Scale17 scores were excluded. Although this makes 
sense in trying to rule out the possibility of the effects of depression on fatigue, it limits 
the generalisability of findings.  In addition, the patients in these three RCTs had low 
mean disability scores (Expanded Disability Status Scale)18 and the majority had 
relapsing remitting MS (see Table).   Fatigue occurs across the board in MS and effective 
interventions are needed for people with higher levels of disability including reduced 
mobility.   
 
Finally, implementation of these interventions in normal everyday health care needs to 
be more carefully considered.  The CBT protocol here included 12 face-to-face sessions 
with an experienced CBT therapist.   Bearing in mind effects were not sustained at long 
term follow-up, this is unlikely to be a cost-effective treatment. CBT therapists 
experienced in treating fatigue are also not readily available to most patients with MS 
fatigue.  The exercise intervention included the provision of home training equipment, 
but only for the duration of the study and only one type of exercise.  Any exercise program 
needs to consider how to embed exercise as a habitual part of an everyday lifestyle that 
can be sustained once the intervention is finished. To do this, exercise needs to consider 
personal preference (enjoyment) of type of exercise and tailoring of exercise during times 
of symptom fluctuation or more serious relapse.   
 
 
REFERENCES: 
1.  van de Akker LE, Beckerman, H, Collette EH et al. Cognitive behavioral therapy 
positively affects fatigue in patients with multiple sclerosis: Results of a randomized 
controlled trial Multiple Sclerosis Journal. 2017; DOI:0.1177/1352458517709361 
2. Hein M, Verschuren O, Hoogervorst ELJ et al. Does aerobic training alleviate 
fatigue and improve societal participation in patients with multiple sclerosis? A 
randomized controlled trial. Multiple Sclerosis Journal.  2017; 
DOI:10.1177/1352458517696596 
3.  Blikman LJ, van Meeteren J, Twisk JWR et al.  Effectiveness of Energy Conservation 
Management on fatigue and participation in Multiple Sclerosis: A Randomized Controlled 
Trial Multiple Sclerosis Journal. 2017; DOI:10.1177/1352458517702751 
4.  Beckerman H, Blikman LJ, Heine M, et al. The effectiveness of aerobic training, 
cognitive behavioural therapy, and energy conservation management in treating MS-
related fatigue: the design of the TREFAMS-ACE programme. Trials. 2013; 14: 250. 
5. Beurskens AJ, Bultmann U, Kant I, Vercoulen JH, Bleijenberg G and Swaen GM. 
Fatigue among working people: validity of a questionnaire measure. Occup Environ 
Med. 2000; 57: 353-7. 
6.  Cardol M, Beelen A, van den Bos GA, de Jong BA, de Groot IJ and de Haan RJ. 
Responsiveness of the Impact on Participation and Autonomy questionnaire. Arch Phys 
Med Rehabil. 2002; 83: 1524-9. 
7.  Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ and Schlech WF. Measuring the 
functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 
1994; 18 Suppl 1: S79-83. 
8.  Krupp LB, LaRocca NG, Muir-Nash J and Steinberg AD. The fatigue severity scale. 
Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch 
Neurol. 1989; 46: 1121-3. 
9.  Heine M, van de Port I, Rietberg MB, van Wegen EE and Kwakkel G. Exercise 
therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2015: CD009956.  
10.  Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: 
updated guidelines for reporting parallel group randomized trials. Ann Intern Med2010: 
152:726-32. doi:10.7326/0003-4819-152-11-201006010-00232 pmid:20335313.  
11. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: 
template for intervention description and replication (TIDieR) checklist and guide. BMJ:  
(Clinical research ed). 2014; 348: g1687. 
12.  Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised 
controlled trials. BMJ : British Medical Journal. 2006;332(7547):969-971. 
13.  Nordin, Å., Taft, C., Lundgren-Nilsson, Å., & Dencker, A. (2016). Minimal 
important differences for fatigue patient reported outcome measures—a systematic 
review. BMC Med Res Methodol. 2016; 26; 16:62. doi: 10.1186/s12874-016-0167-6. 
14. White, I. R. (2009). Multivariate random-effects meta-analysis. Stata Journal, 
9(1), 40. 
15. Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. 
Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: 
a systematic review and meta-analysis. Archives of Physical Medicine and Rehabilitation 
2013; 94(7): 1360-1376 
16. Moore Graham F, Audrey Suzanne, Barker Mary, Bond Lyndal, Bonell Chris, 
Hardeman Wendy et al. Process evaluation of complex interventions: Medical Research 
Council guidance BMJ 2015; 350 :h1258 
17. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr 
Scand 1983, 67:361–370. 
18. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded 
disability status scale (EDSS). Neurology 1983, 33:1444–1452. 
 
  
 Table: Summary comparison of the three TREFAMS-ACE Randomised Controlled Trials   
Study reference 
 
N 
Demographic and Disease Factors   
Female (%); (RRMS (%); Age years M (SD)  
EDDS Level of disability Median (range)  
Time since diagnosis Median years (range) 
 
Experimental                 Control  
Lost to end of 
treatment 
follow-up % 
(drop out + non-
response) 
       
      Exp       Con 
Lost to 52-week 
follow up % 
(drop out + non-
response) 
% Analysed in 
ITT  
Exp           Con 
Summary of theory/ 
rationale behind 
treatment 
Who delivered 
treatment 
 
(level of training) 
Timing & Mode of 
Delivery  
 
(week x frequency x 
minutes (mode)) 
Cognitive 
Behavioural 
Therapy (CBT) 
 
van de Akker et al. 
2017 
n=44 
 
Female: 71%,  
 
RRMS 73 % 
 
Age: 51 (8.3)   
 
EDSS: 3 (2.8- 3.6)  
 
MS length  
8.2 (2.9 – 14.2)  
n=47 
 
Female: 83%,  
 
RRMS 75% 
 
Age: 46 (11.6)   
 
EDSS: 2.5 (2.3 -3.0)  
 
MS length  
5.2 (2.1 – 11.5) 
   14%         22% 
 
   11%         26% 
ITT 
 100%           98% 
Cognitive behavioural 
model of MS fatigue:- 
disease factors trigger 
fatigue in MS, and 
cognitive, emotional, 
and behavioural 
factors perpetuate the 
severity and impact of 
fatigue. 
CBT for MS fatigue 
aims to influence 
cognitions, behaviours 
and emotions that 
perpetuate fatigue. 
6 CBT    
state-certified 
healthcare 
psychologists 
 
Received 3 day 
training in this 
protocol. 
Supervised 
every second 
week by a 
supervising CBT 
psychologist 
12 x 45 minute (face-
to-face) individual 
outpatient sessions 
over 16 weeks) 
 
Therapy tailored to 
patients’ individual 
needs.  
Aerobic exercise 
Hein et al., 2017 
n=43 
 
Female: 74%,  
 
RRMS: 73%;  
 
Age: 43 (9.8)   
 
EDSS: 2.5 (2.0- 3.5)  
 
MS length 
7.0 (2.0 – 10.0)  
n=46 
 
Female: 72%,  
 
RRMS:74%; 
 
Age: 48 (9.2)   
 
EDSS: 3.0 (2.0-4.0)  
 
MS length 
12.0 (2.0 – 19.0)  
   14%         19% 
 
 
   23%         35% 
ITT 
 100%        100% 
Aerobic exercise may 
result in 
improvements 
through increased 
fitness, normalisation 
of hormonal functions, 
& changes in 
neuroinflammatory & 
neuroprotective 
biomarkers. 
6 trained 
physiotherapists 
Experienced in 
treating MS 
patients.  
Specific trial 
intervention 
training not 
reported.  
12 individually 
supervised 45 minute 
outpatient aerobic 
interval training 
sessions on Kettler x7 
home trainer over 16 
weeks  
Regular prescribed 
home exercise over 16 
weeks on Kettler x7 
home trainer  
provided for duration 
of study.  
Energy 
Conservation  
Management 
(ECM) 
 
Blikman et al. 2017 
n=42 
 
Female: 81%  
 
RRMS: 76% 
 
Age: 48 (11.0)   
 
EDSS: 2.5 (2-4)  
 
 
MS length 
6.5 (3.7-17.4)  
n=44 
 
Female: 68%  
 
RRMS 73% 
 
Age 47 (11.5)   
 
EDSS: 3 (2.8-3.6)  
 
MS length 
7.5 (3-14)  
 
   14%         9% 
 
    19%         20% 
ITT 
 88%           91% 
Aims to promote a 
positive attitude 
towards active 
decision-making and 
the optimum use of 
the available energy to 
fit the unique needs of 
individuals. ECM aims 
to reduce the impact 
and severity of fatigue, 
to increase 
patients’ use of 
energy-conserving 
strategies and to 
improve their 
confidence in their 
ability to 
manage fatigue. 
4 x occupational 
therapists 
familiar with MS 
& ECM & 
qualified in 
motivational 
interviewing   
Training 
included 
programme 
guideline and 1 
day ECM 
refresher course 
12 x 45 minute (face-
to-face) individual 
sessions over 16 
weeks 
 
Patients given an ECM 
workbook 
Abbreviations: Cognitive Behavioural Therapy (CBT); CON (Nurse-led Control group); ECM (Energy 
Conservation Management); EDSS (Expanded Disability Status Scale); EXP (Experimental intervention group); 
RRMS (Relapse-Remitting Multiple Sclerosis).  
  
Figure legend: Standardised mean differences for each intervention compared to control. Negative 
values favour intervention. 
 
 
